Pancreatic Cancer Research

ResearcherSouth Texas Veterans Health Care SystemNo recent work listed

James W. Freeman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5758-325X; OpenAlex author ID A5101626475; NIH RePORTER profile ID 1897559. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
3
Labs led
1
Collaborators
16
Papers, trials and grants by year

2013: 3 papers · 2014: 2 papers, 2 grants · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 grant · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 8

  1. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching. Last author DOI 10.1038/s41419-022-05103-1↗
  2. Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells. Co-author DOI 10.1002/mc.22503↗
  3. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy. Last author DOI 10.1158/1078-0432.ccr-15-3115↗
  4. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-1664↗
  5. A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer. Last author DOI 10.1371/journal.pone.0106343↗
  6. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Co-author DOI 10.1038/cddis.2013.259↗
  7. Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. Last author DOI 10.1038/oncsis.2013.36↗
  8. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Last author DOI 10.1186/1476-4598-12-104↗

Grants 3

  1. Role of CD44 in adaptive plasticity of pancreatic cancer I01BX002962↗
  2. Role of Ron kinase in pancreatic cancer I01BX000927↗
  3. Role of TGFBeta alterations in pancreatic cancer R01CA069122↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Addanki Pratap Kumar · 4 shared papers, 2014–2022 · strength 0.35
  2. Shujie Zhao · 3 shared papers, 2013–2022 · strength 0.28
  3. Chen Chen · 1 shared paper, 2022 · strength 0.17
  4. Kolaparthi Venkatasubbarao · 2 shared papers, 2013–2014 · strength 0.09
  5. Steffan T. Nawrocki · 2 shared papers, 2013 · strength 0.08
  6. Amanda R. Muñoz · 1 shared paper, 2017 · strength 0.07
  7. Rita Ghosh · 1 shared paper, 2017 · strength 0.07
  8. Jingjing Gong · 1 shared paper, 2017 · strength 0.07
  9. Shujun Zhao · 1 shared paper, 2013 · strength 0.06
  10. Alakesh Bera · 1 shared paper, 2014 · strength 0.06
  11. Jennifer S. Carew · 1 shared paper, 2013 · strength 0.04
  12. Susan M Fischer · 1 shared paper, 2014 · strength 0.04
  13. Divya Chakravarthy · 1 shared paper, 2014 · strength 0.04
  14. Jingjing Gong · 1 shared paper, 2014 · strength 0.04
  15. Huamin Wang · 1 shared paper, 2014 · strength 0.04
  16. Scott Kopetz · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.